Aby J. Mathew Sells 7,604 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 7,604 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares in the company, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

BioLife Solutions Stock Up 4.9 %

Shares of NASDAQ BLFS opened at $27.39 on Friday. The business’s fifty day moving average price is $24.86 and its 200-day moving average price is $23.68. BioLife Solutions, Inc. has a one year low of $14.50 and a one year high of $28.88. The stock has a market capitalization of $1.27 billion, a PE ratio of -25.84 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

Analyst Ratings Changes

Several research firms have commented on BLFS. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday. TD Cowen boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. KeyCorp lifted their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, HC Wainwright reduced their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.00.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stifel Financial Corp raised its position in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after purchasing an additional 670 shares during the period. Louisiana State Employees Retirement System grew its stake in BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after buying an additional 700 shares in the last quarter. GAMMA Investing LLC raised its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 748 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock worth $296,000 after acquiring an additional 753 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the third quarter worth $28,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.